Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

Although combination therapy including chemotherapy and immune checkpoint inhibitors (ICIs) improves overall survival (OS) of patients with non-small-cell lung cancer (NSCLC), there is a higher incidence of adverse events and treatment discontinuation. Since programmed death-ligand 1 (PD-L1) could n...

Full description

Bibliographic Details
Main Authors: Chian-Wei Chen, Chien-Yu Lin, Jeng-Shiuan Tsai, Chia-Yin Lin, Chao-Chun Chang, Yi-Ting Yen, Yau-Lin Tseng, Po-Lan Su, Chien-Chung Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
neutrophil-to-lymphocyte ratio
non-small-cell lung cancer
chemotherapy
immune checkpoint inhibitors
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1238876/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1238876/full

Similar Items